Enoxaparine

Phase 3Small molecule

Sanofi

Enoxaparine is one of 133 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

132

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

AbortionActive, not recruiting

MortalityActive, not recruiting

Pancreatic CancerActive, not recruiting

Venous ThromboembolismPhase 2

Active, not recruiting

AbortionPhase 3

Active, not recruiting

MortalityPhase 3

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Enoxaparine

Sanofi

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Medrol

1 4

Byetta

AstraZeneca

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Meglitinides

Sanofi

Preclinical

1 7

Chemotherapy Agents

Takeda

Preclinical

1 8

Secretin-Ferring

Ferring

Preclinical

1 9

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

2 10

Biguanides

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Critically Ill Patients1 trial

The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients

Completed·SShaare Zedek Medical Center·Phase 4·NCT00351663·39 enrolled

Local1 trial

ARIXTRA Local Study For Registration In China.

Completed· GSK logo

GSK·Phase 3·NCT00328939·240 enrolled

Abortion1 trial

Prevention of Unexplained Recurrent Abortion by Enoxaparine

Terminated·UUniversity Hospital, Brest·Phase 3·NCT00740545·258 enrolled

Venous Thromboembolism1 trial

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

Completed· Bayer logo

Bayer·Phase 2·NCT00402467·613 enrolled

Mortality1 trial

Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients

Suspended·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02271295·16 enrolled

2 more indications

Hemodialysis1 trial

HENOX: Enoxaparine in Hemodialysis

Completed· Sanofi logo

Sanofi·Phase 4·NCT00347490·100 enrolled

Pancreatic Cancer1 trial

Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer

Completed·CCONKO-Studiengruppe·Phase 1/2·NCT01945879·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Enoxaparine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enoxaparine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enoxaparine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Enoxaparine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Critically Ill Patients1 trial

Local1 trial

Abortion1 trial

Venous Thromboembolism1 trial

Mortality1 trial

Hemodialysis1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News